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Why read this summary?
Osteoarthritis refers to a syndrome of joint pain
accompanied by functional limitation and reduced
quality of life. It is the most common form of arthritis
and one of the leading causes of pain and disability in
the United Kingdom. The published evidence for
osteoarthritis treatment has many limitations—typi-
cally, short duration studies using single drug treat-
ments. However, people with osteoarthritis need to be
aware of the treatments that represent core manage-
ment and of the range of additional treatments
available. This article summarises the most recent
recommendations from the National Institute for
Health and Clinical Excellence (NICE) on the care
and management of osteoarthritis in adults.1
Recommendations
NICErecommendationsarebasedonsystematicreviews
of best available evidence. When minimal evidence is
available, recommendations are based on the guideline
development group’s opinion of what constitutes good
practice. Evidence levels for the recommendations are in
the longer version of this article on bmj.com.
Holistic assessment and management of symptomatic
osteoarthritis
 Assess the effect of osteoarthritis on the indivi-
dual’s function, quality of life, occupation, mood,
relationships, and leisure activities.
 Provide periodic review tailored to an indivi-
dual’s needs.
 Formulate a management plan in partnership
with the person with osteoarthritis, taking into
consideration comorbidities that compound the
effect of osteoarthritis.
 Communicate the risks and benefits of treatment
options in ways that can be understood.
Core treatments
Provide advice on the following to all people with
symptomatic osteoarthritis:
 Access to appropriate information, oral and written, to
enhance understanding of the condition and to counter
misconceptions (such as osteoarthritis is inevitably
progressive and cannot be treated). Good sources of
patient information exist online at www.arc.org.uk
(Arthritis Research Campaign), www.move.uk.net
(Move), and www.arthritiscare.org.uk (Arthritis Care).
 Activity and exercise, including local muscle
strengthening and general aerobic fitness.
 Interventions to achieve weight loss if person is
overweight or obese.
Other treatments can be used as adjuncts to these
core treatments (see figure), and a person with
osteoarthritis may use several of these treatments.
Some treatments will be useful only for certain joints.
Adjunct non-pharmacological treatments
 Agree on self management strategies with the person
with osteoarthritis, emphasising the recommended
core treatments, especially exercise.
 Target positive behavioural changes as appro-
priate—such as exercise, weight loss, use of
suitable footwear (that is, with shock absorbing
properties) and pacing (avoiding “peaks” and
“troughs” of activities).
 Consider other therapies, such as:
- Local heat or cold applications
-Manipulation and stretching, particularly for
osteoarthritis of the hip
- Transcutaneous electrical nerve stimulation
(TENS)
-Assessment for bracing, joint supports, or insoles in
those with biomechanical joint pain or instability
-Assistive devices (for example, walking sticks and
tap turners) for those who have specific problems
with activities of daily living. Expert advice may be
sought, for example, from occupational therapists
or disability equipment assessment centres.
Electroacupuncture should not be used. Insufficient
evidence exists (despite RCTs and cost effectiveness
analysis) to make a firm recommendation on acupunc-
ture. The use of glucosamine and chondroitin products
is not recommended.
Adjunct pharmacological treatments
Consider risks and benefits of pharmacological treat-
ments, particularly in elderly people and those with
comorbidities.
This is one of a series of BMJ
summaries of new guidelines,
which are based on the best
available evidence; they will
highlight important
recommendations for clinical
practice, especially where
uncertainty or controversy exists.
Further information about the
guidance, a list of members of the
guideline development group, and
the supporting evidence
statements are in the version on
bmj.com.
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 Offer paracetamol for pain relief—regular dosing
may be needed.
 For knee and hand osteoarthritis, consider para-
cetamol and/or topical non-steroidal anti-inflam-
matory drugs (NSAIDs) before oral NSAIDs,
cyclo-oxygenase-2 (COX 2) inhibitors, and
opioids.
 Consider topical capsaicin.
 If paracetamol or topical NSAIDs are insufficient
for pain relief, then consider adding opioid
analgesics or substituting with (or in addition to
paracetamol) an oral NSAID or COX 2 inhibitor.
 Use oral NSAIDs or COX 2 inhibitors at the
lowest effective dose for the shortest possible
period of time. The first choice should be either a
COX 2 inhibitor (other than etoricoxib 60 mg) or
a standard NSAID. In either case, prescribe these
alongside a proton pump inhibitor, choosing the
one with the lowest acquisition cost.
 All oral NSAIDs and COX-2 inhibitors have
analgesic effects of a similar magnitude but vary
in their potential gastrointestinal, liver, and
cardiorenal toxicity; therefore, when choosing
the agent and dose, take into account an
individual’s risk factors (including age) and
consider appropriate assessment and/or ongoing
monitoring of these risk factors.
 If a person with osteoarthritis needs to take low
dose aspirin, consider other analgesics before
substituting with or adding an NSAID or COX 2
inhibitor (plus a proton pump inhibitor) if pain
relief is ineffective or insufficient.
 Consider intra-articular corticosteroid injections
for the relief of moderate to severe pain.
Rubefacients and intra-articular hyaluronan injec-
tions are not recommended for the treatment of
osteoarthritis.
Referral for surgical interventions
 Referral for arthroscopic lavage and debridement
should not be routinely offered as part of
treatment for osteoarthritis, unless the person
has knee osteoarthritis with a clear history of
mechanical locking (therefore not for reasons
such as gelling (stiffness and pain associated with
prolonged immobility) “giving way,” or x ray
evidence of loose bodies—currently common
inappropriate reasons for referral).
 Before referring a patient for consideration of
joint surgery, ensure that he or she has been
offered at least the core treatment options.
 Consider referral for joint replacement surgery
for people with osteoarthritis who have joint
symptoms (pain, stiffness, and reduced function)
that substantially affect their quality of life and
are refractory to non-surgical treatment. Referral
should be made before there is prolonged and
established functional limitation and severe pain.
 Patient specific factors (including age, sex, smok-
ing, obesity, and comorbidities) should not be
barriers to referral for joint replacement surgery.
 Base decisions about referral thresholds on
discussions between patient representatives,
referring clinicians, and surgeons, rather than
on current scoring tools for prioritisation.
Overcoming barriers
Improved understanding, among healthcare profes-
sionals and people with osteoarthritis, of the range of
treatments available will reduce misconceptions and
negativity about osteoarthritis and its treatment.
Emphasising the recommended core treatments,
other simple, non-pharmacological treatments, and
relatively safe agents such as paracetamol and topical
NSAIDswill help to reduce drug toxicity and the focus
on pharmacological treatments.
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Treatments for osteoarthritis in adults. Starting at the centre and working outwards, the
treatments are arranged in the order in which they should be considered, taking into account
individuals’ different needs, risk factors, and preferences. The core treatments (centre) should be
considered first for every person with osteoarthritis. If further treatment is required, consider the
drugs in the second circle before the drugs in the outer circle. The outer circle also shows
adjunctive treatments (both non-pharmacological and surgical), which have less well proved
efficacy, provide less symptom relief, or increased risk to the patient compared with those in the
second circle
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